Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 4,900,000 shares, an increase of 6.1% from the May 31st total of 4,620,000 shares. Based on an average trading volume of 1,480,000 shares, the days-to-cover ratio is presently 3.3 days.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ADAP shares. Scotiabank started coverage on shares of Adaptimmune Therapeutics in a report on Thursday, May 30th. They set a “sector outperform” rating and a $3.15 price target on the stock. Mizuho dropped their price objective on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, May 17th. Finally, StockNews.com raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 3rd.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Columbia Advisory Partners LLC bought a new stake in shares of Adaptimmune Therapeutics during the first quarter valued at approximately $25,000. JTC Employer Solutions Trustee Ltd bought a new stake in Adaptimmune Therapeutics in the first quarter worth $41,000. Twin Focus Capital Partners LLC bought a new stake in Adaptimmune Therapeutics in the fourth quarter worth $44,000. Harbor Capital Advisors Inc. increased its position in Adaptimmune Therapeutics by 9.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 13,317 shares during the last quarter. Finally, Boulder Hill Capital Management LP bought a new stake in Adaptimmune Therapeutics in the first quarter worth $143,000. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Stock Performance

NASDAQ ADAP opened at $1.05 on Wednesday. Adaptimmune Therapeutics has a 12 month low of $0.42 and a 12 month high of $2.05. The stock has a market cap of $259.16 million, a price-to-earnings ratio of -1.42 and a beta of 2.31. The company’s 50 day moving average is $1.05 and its two-hundred day moving average is $1.10.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Wednesday, May 15th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $4.40 million. Adaptimmune Therapeutics had a negative net margin of 890.13% and a negative return on equity of 259.68%. Sell-side analysts forecast that Adaptimmune Therapeutics will post -0.61 EPS for the current year.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.